TY - JOUR
T1 - A Novel Capsule-Delivered Enteric Drug-Injection Device for Delivery of Systemic Biologics
T2 - A Pilot Study in a Porcine Model
AU - Sarker, Sunandita
AU - Wankum, Ben
AU - Perey, Trevor
AU - Mau, Musharrat Mustaree
AU - Shimizu, Jeff
AU - Jones, Ryan
AU - Terry, Benjamin
N1 - Publisher Copyright:
© 1964-2012 IEEE.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Innovative swallowable capsule technologies such as drug-loaded, dissolvable microneedles, mucoadhesive patches, and various microdevices present unique drug-carrying capabilities to overcome challenges regarding oral delivery of biologics. Here, we report a swallowable capsule for intestinal drug delivery (SCIDD) with the potential of directly injecting biological therapeutics into the insensate small intestine wall. The design, optimization, and validation of the SCIDD's primary subsystems were performed both ex-vivo and in-vivo. The assembled capsule was further tested in vivo to validate the actuation sequence and showed a 70% (n = 17) success rate in an animal model. Additionally, a drug delivery study indicated systemic uptake of adalimumab via SCIDD compared with luminal delivery in the small intestine. The pilot study presented here establishes that the novel platform could be used to orally deliver systemic biologics.
AB - Innovative swallowable capsule technologies such as drug-loaded, dissolvable microneedles, mucoadhesive patches, and various microdevices present unique drug-carrying capabilities to overcome challenges regarding oral delivery of biologics. Here, we report a swallowable capsule for intestinal drug delivery (SCIDD) with the potential of directly injecting biological therapeutics into the insensate small intestine wall. The design, optimization, and validation of the SCIDD's primary subsystems were performed both ex-vivo and in-vivo. The assembled capsule was further tested in vivo to validate the actuation sequence and showed a 70% (n = 17) success rate in an animal model. Additionally, a drug delivery study indicated systemic uptake of adalimumab via SCIDD compared with luminal delivery in the small intestine. The pilot study presented here establishes that the novel platform could be used to orally deliver systemic biologics.
KW - Ingestible Capsule robots
KW - biologics
KW - drug delivery
KW - peptide delivery
UR - http://www.scopus.com/inward/record.url?scp=85120033468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120033468&partnerID=8YFLogxK
U2 - 10.1109/TBME.2021.3129653
DO - 10.1109/TBME.2021.3129653
M3 - Article
C2 - 34807818
AN - SCOPUS:85120033468
SN - 0018-9294
VL - 69
SP - 1870
EP - 1879
JO - IEEE Transactions on Biomedical Engineering
JF - IEEE Transactions on Biomedical Engineering
IS - 6
ER -